Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.

Abstract

Clinical response that was achieved by patients receiving golimumab through 24 weeks was sustained through 52 and 104 weeks.

The golimumab safety profile appeared to be consistent with the known safety profile of tumour necrosis factor inhibitors.

Full Text

• DOI - Annals of the rheumatic diseases (DOI)
• UK PubMed Central - full-text online
• PubMed Central - full-text online
• Ovid Technologies, Inc. - full-text online
• Lippincott Williams & Wilkins - full-text online
• HighWire Press - full-text online
• HighWire Press - full-text online
• EBSCO - full-text online
• PubMed Central Canada - full-text online

Subjects

• Antibodies, Monoclonal
• Back Pain
• Cross-Over Studies
• Double-Blind Method
• Drug Resistance
• Drug Substitution
• Drug Therapy, Combination
• Health Status
• Humans
• Immunologic Factors
• Injections, Subcutaneous
• Joints
• Severity of Illness Index
• Spondylitis, Ankylosing
• Treatment Outcome

Similar articles

• Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GO-FORWARD Study Extension. (2013-05-15)
• Golimumab for rheumatoid arthritis: a systematic review. (2010-06-02)
• Golimumab, a human antibody to TNF-{alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate: The GO-FORWARD Study. (2008-12-16)
• Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. (2012-11-17)
• Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. (2009-04-07)
• Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. (2010-05-25)
• Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. (2010-04-14)
• Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. (2008-11-10)
• Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. (2012-09-11)

Authors

• Jürgen Braun
• Atul Deodhar
• Robert D Inman
• Désirée van der Heijde
• Michael Mack
• Stephen Xu
• Benjamin Hsu

Publication date

2012-04-11

Journal

Journal topics

• Rheumatic Diseases

Language

Eng.

Copyright

Annals of the rheumatic diseases

Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, D-44652 Herne, Germany. j.braun [at] rheumazentrum-ruhrgebiet.de

Release reference

Ann Rheum Dis. 2012 May;71(5):661-7

Related books

• Books of Antibodies, Monoclonal
• Books of Back Pain
• Books of Cross-Over Studies
• Books of Double-Blind Method
• Books of Drug Resistance
• Books of Drug Substitution
• Books of Drug Therapy, Combination
• Books of Health Status
• Books of Immunologic Factors
• Books of Injections, Subcutaneous
• Books of Joints
• Books of Rheumatic Diseases
• Books of Severity of Illness Index
• Books of Spondylitis, Ankylosing
• Books of Treatment Outcome